Home Healthcare Pharmaceuticals Parkinson's Disease Drugs Market

Parkinson's Disease Drugs Market Size, Share & Trends Analysis Report By Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, Other Mechanisms of Action) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format: | Report Code: SR3530DR | Pages: 156
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Parkinson's Disease Drugs Market, By Mechanism of Action 2022-2034 (USD MILLION/ Units)
    1. Dopamine Agonists
    2. Anticholinergic
    3. MAO-B inhibitors
    4. Amantadine
    5. Carbidopa-levodopa
    6. COMT Inhibitors
    7. Other Mechanisms of Action 
  2. Regional Parkinson's Disease Drugs Market
    1. North America
      1. North America Parkinson's Disease Drugs Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      2. U.S.
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      3. Canada
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
    2. Europe
      1. Europe Parkinson's Disease Drugs Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      2. U.K.
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      3. Germany
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      4. France
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      5. Spain
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      6. Italy
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      7. Russia
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      8. Nordic
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      9. Benelux
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      10. Rest of Europe
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
    3. APAC
      1. APAC Parkinson's Disease Drugs Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      2. China
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      3. Korea
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      4. Japan
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      5. India
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      6. Australia
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      7. Singapore
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      8. Taiwan
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      9. South East Asia
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      10. Rest of Asia-Pacific
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
    4. Middle East and Africa
      1. Middle East and Africa Parkinson's Disease Drugs Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      2. UAE
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      3. Turkey
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      4. Saudi Arabia
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      5. South Africa
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      6. Egypt
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      7. Nigeria
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      8. Rest of MEA
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
    5. LATAM
      1. LATAM Parkinson's Disease Drugs Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      2. Brazil
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      3. Mexico
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      4. Argentina
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      5. Chile
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      6. Colombia
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
      7. Rest of LATAM
        1. Dopamine Agonists
        2. Anticholinergic
        3. MAO-B inhibitors
        4. Amantadine
        5. Carbidopa-levodopa
        6. COMT Inhibitors
        7. Other Mechanisms of Action 
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.